Get the Stockscreener App
38.82
2.95%
-1.18
After Hours:
38.82
Tarsus Pharmaceuticals Inc stock is traded at $38.82, with a volume of 622.29K.
It is down -2.95% in the last 24 hours and down -4.17% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$40.00
Open:
$39.78
24h Volume:
622.29K
Relative Volume:
0.99
Market Cap:
$1.63B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-8.3664
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-8.53%
1M Performance:
-4.17%
6M Performance:
-27.79%
1Y Performance:
+59.82%
1-Day Range:
$38.80
$40.49
1-Week Range:
$38.80
$42.54
52-Week Range:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
38.82 | 1.68B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
What are the latest earnings results for Tarsus Pharmaceuticals Inc.Financial News Forecasts For Smart Trading - jammulinksnews.com
Is Tarsus Pharmaceuticals Inc. a growth stock or a value stockTop Growth Data Feed From AI Tools - jammulinksnews.com
Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q2 2025 Financial Results and Corporate Update - Quiver Quantitative
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewswire
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewswire Inc.
Why Investors Shouldn't Be Surprised By Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) P/S - simplywall.st
Tarsus Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayWeekly Return Pick Forecast Reports Show Trend - metal.it
Tarsus Pharmaceuticals Inc. Charts Flash Early Recovery SignalsNews Based Entry Opportunity Alerts Detected - metal.it
Wyckoff Accumulation Phase Possible in Tarsus Pharmaceuticals Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Evaluating Tarsus Pharmaceuticals Inc. with trendline analysisTechnical Screener for High Growth Stocks - Newser
How Resilient Is Tarsus Pharmaceuticals Inc. Stock During Economic DownturnsBuy Strategy Tracker with Growth Indicators - Newser
Tarsus Pharmaceuticals Inc. Attempts Reversal From Key SupportChart Driven High Reward Trading Setup Presented - metal.it
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionTrade Safety Matrix for Conservative Traders - Newser
Published on: 2025-07-28 23:18:28 - metal.it
Fibonacci Levels Suggest Recovery for Tarsus Pharmaceuticals Inc.Weekly Chart Analysis With Entry Advice Provided - metal.it
How volatile is Tarsus Pharmaceuticals Inc. stock compared to the marketTriple-digit profit margins - jammulinksnews.com
Published on: 2025-07-27 21:08:22 - jammulinksnews.com
Is it the right time to buy Tarsus Pharmaceuticals Inc. stockFree Investment Timing Strategies - jammulinksnews.com
Tarsus Pharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsFree Access to Community - metal.it
How does Tarsus Pharmaceuticals Inc. generate profit in a changing economyCapitalize on market trends with confidence - jammulinksnews.com
Buy Signal for Tarsus Pharmaceuticals Inc. Stock Key Technical Indicators to WatchPotential Rocket List - metal.it
Is Tarsus Pharmaceuticals Inc. stock overvalued or undervaluedCapitalize on fast-moving market trends - jammulinksnews.com
What is the dividend policy of Tarsus Pharmaceuticals Inc. stockPhenomenal capital appreciation - jammulinksnews.com
How Interest Rate Changes Impact Tarsus Pharmaceuticals Inc. Stock PerformanceMomentum Swing Watchlist - Newser
What is the risk reward ratio of investing in Tarsus Pharmaceuticals Inc. stockDiscover the next big stock winners - jammulinksnews.com
Bank of New York Mellon Corp Sells 915 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
What analysts say about Tarsus Pharmaceuticals Inc. stockExceptional financial outcomes - PrintWeekIndia
Should I buy Tarsus Pharmaceuticals Inc. stock before earningsHigh-yield investments - jammulinksnews.com
When is the best time to buy Tarsus Pharmaceuticals Inc. stockHigh-yield market plays - jammulinksnews.com
Is Tarsus Pharmaceuticals Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To Profitability - Yahoo Finance
Tarsus Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - Autocar Professional
Arizona State Retirement System Purchases 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
What drives Tarsus Pharmaceuticals Inc. stock priceBreakthrough wealth creation - Autocar Professional
What makes Tarsus Pharmaceuticals Inc. stock price move sharplyFree Stock Movement Tracking - Newser
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Tarsus Pharmaceuticals (TARS) and Abbott Laboratories (ABT) - The Globe and Mail
Tarsus Pharmaceuticals Shares Soar 4.47% on Strong Sales, Earnings - AInvest
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):